ZHENG Jiwen, WANG Jin, LI Huashan. Phased perioperative management of colorectal cancer from the perspective of collateral diseases[J]. Modern Chinese Clinical Medicine, 2023,30(1):87-89.
ZHENG Jiwen, WANG Jin, LI Huashan. Phased perioperative management of colorectal cancer from the perspective of collateral diseases[J]. Modern Chinese Clinical Medicine, 2023,30(1):87-89. DOI: 10.3969/j.issn.2095-6606.2023.01.021.
Colorectal cancer is a common type of malignant tumor of the digestive tract that covers the entire section from the rectum to the cecum
and its incidence is increasing year by year. The
Case Records as a Guide to Clinical Practice
for the first time put forward the concept of "collateral diseases"
to which "abdominal mass" belongs
thus establishing the theory about tumor based on collateral diseases. Colorectal cancer can be classified as "abdominal mass"
"accumulation-gathering" and "intestinal tumor" in traditional Chinese medicine. Based on the theory of collateral diseases
TCM phased treatment and recovery programs are implemented for perioperative management of patients with colorectal cancer: Before the operation
it is key to dispel phlegm and remove blood stasis
resolve toxins and unblock the collaterals
and remove the pathogenic factors in the collaterals. During the operation
the focus should be placed on supplementing qi and nourishing the blood
fortifying the spleen and dredging the bowels
and warming and unblocking the collaterals. After the operation
the priority becomes supplementing the spleen and nourishing the kidney
supplementing weakness and reconciling the collaterals
and removing the residual toxins. Combined with clinical cases
this paper elaborates on the perioperative management of colorectal cancer based on the theory of collateral diseases.
关键词
大肠癌络病中医药治疗分期论治
Keywords
colorectal cancercollateral diseasestreatment of traditional Chinese medicinephased treatment
references
BRAY F,FERLAY J,SOERJOMATARAM I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6): 394-424.